The New York Times

Silicon Valley Wants to Build A.I. That Can Improve A.I. on Its Own

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...
InfoQ

MIT's Recursive Language Models Improve Performance on Long-Context Tasks

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...
IGN

"We resolved to move forward with our original vision."

Nintendo has said it was unwilling to backtrack on the design of Metroid Prime 4: Beyond's controversial open world hub despite seeing "changed" attitudes to open-world games, as the project had ...
Seeking Alpha

Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Benzinga.com

Why Are Shares Of Recursion Pharmaceuticals Higher Today?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
STAT

Recursion’s incoming CEO: Beyond hype on AI-driven drug development, it’s time to show results

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
Seeking Alpha

Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...
Forbes

Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
The Motley Fool

Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...
STAT

Recursion CEO Chris Gibson out as company head after 12 years

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
techannouncer

Mastering LeetCode: Comprehensive Python Solutions and Strategies

Getting a handle on LeetCode can feel like a big task, especially when you’re starting out. But with the right approach and tools, it becomes much more manageable. Python, with its clear syntax and ...